eligibility_summary
Eligibility: age 16–90, histologic brain glioma (primary/relapsed/metastatic), failed/no standard therapy, life expectancy >3 mo, KPS≥60 or ECOG 0–2, fit for biopsy/resection or malignant fluid for TILs, ≥1 evaluable lesion, adequate labs/organ function, contraception, stop anti-tumor therapy ≥28 d, consent/compliance. Exclude: high-dose steroids/autoimmune tx, poor lung/cardiac function, active infections (HIV/HBV/HCV/syphilis), severe irAE/unresolved AEs, pregnancy, prior transplants/dialysis, major comorbidity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Phase I/II single‑arm trial in advanced brain cancers (gliomas, glioblastoma, meningioma) testing: 1) Autologous tumor‑infiltrating lymphocyte (TIL) therapy—personalized adoptive cell transfer, patient tumor T cells are expanded ex vivo and reinfused after non‑myeloablative lymphodepletion with cyclophosphamide (alkylating agent) and fludarabine (purine analog) to enhance engraftment. 2) Aldesleukin (IL‑2)—cytokine therapy that drives T‑cell proliferation/activation via IL‑2 receptor signaling. 3) Pembrolizumab—anti‑PD‑1 monoclonal antibody checkpoint inhibitor that blocks PD‑1 on T cells to restore antitumor activity. Targets/pathways: intratumoral cytotoxic T cells, PD‑1/PD‑L1 axis, IL‑2/JAK‑STAT signaling, and reduction of suppressive immune cells (e.g., regulatory T cells) via lymphodepletion.